Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or... Diabetes Ther (2018) 9:1169–1184 https://doi.org/10.1007/s13300-018-0429-x ORIGINAL RESEARCH Treatment Intensification in Type 2 Diabetes: A Real- World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin . . . . Lawrence Blonde Denis Raccah Elisheva Lew Juliana Meyers . . . . Elena Nikonova Mayank Ajmera Keith L. Davis Monica Bertolini Bruno Guerci Received: January 23, 2018 / Published online: April 19, 2018 The Author(s) 2018 receptor agonists (GLP-1 RAs), or basal insulin ABSTRACT in a real-world setting. Methods: Adults with T2D on OAD monother- Introduction: Treatment guidelines recom- apy were identified in the MarketScan claims mend a stepwise approach to glycemia man- database (2007–2014). Those initiating two agement in patients with type 2 diabetes (T2D), OADs (simultaneously or sequentially), GLP-1 but this may result in uncontrolled glycated RAs, or basal insulin were selected (date of ini- hemoglobin A1c (HbA1c) between steps. This tiation was termed the ‘index date’); patients retrospective analysis compared clinical and were required to have HbA1c [ 7.0% in the economic outcomes among patients with 6 months pre-index date. HbA1c was compared uncontrolled T2D initiating two oral antidia- from 6 months pre- to 1-year post-index. betes drugs (OADs), glucagon-like peptide-1 Annual all-cause healthcare utilization and costs http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetes Therapy Springer Journals

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin

Download PDF
16 pages

Loading next page...
 
/lp/springer_journal/treatment-intensification-in-type-2-diabetes-a-real-world-study-of-2-usmhhnPeq0
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Diabetes; Cardiology; Endocrinology
ISSN
1869-6953
eISSN
1869-6961
DOI
10.1007/s13300-018-0429-x
Publisher site
See Article on Publisher Site

Abstract

Diabetes Ther (2018) 9:1169–1184 https://doi.org/10.1007/s13300-018-0429-x ORIGINAL RESEARCH Treatment Intensification in Type 2 Diabetes: A Real- World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin . . . . Lawrence Blonde Denis Raccah Elisheva Lew Juliana Meyers . . . . Elena Nikonova Mayank Ajmera Keith L. Davis Monica Bertolini Bruno Guerci Received: January 23, 2018 / Published online: April 19, 2018 The Author(s) 2018 receptor agonists (GLP-1 RAs), or basal insulin ABSTRACT in a real-world setting. Methods: Adults with T2D on OAD monother- Introduction: Treatment guidelines recom- apy were identified in the MarketScan claims mend a stepwise approach to glycemia man- database (2007–2014). Those initiating two agement in patients with type 2 diabetes (T2D), OADs (simultaneously or sequentially), GLP-1 but this may result in uncontrolled glycated RAs, or basal insulin were selected (date of ini- hemoglobin A1c (HbA1c) between steps. This tiation was termed the ‘index date’); patients retrospective analysis compared clinical and were required to have HbA1c [ 7.0% in the economic outcomes among patients with 6 months pre-index date. HbA1c was compared uncontrolled T2D initiating two oral antidia- from 6 months pre- to 1-year post-index. betes drugs (OADs), glucagon-like peptide-1 Annual all-cause healthcare utilization and costs

Journal

Diabetes Therapy – Springer Journals

Published: Apr 19, 2018

References

  • Standards of medical care in diabetes—2017
  • Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary
    Garber, AJ
  • Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary
    Garber, AJ; Abrahamson, MJ; Barzilay, JI
  • Slow response to loss of glycemic control in type 2 diabetes mellitus
    Brown, JB; Nichols, GA
  • Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people
    Khunti, K; Wolden, ML; Thorsted, BL; Andersen, M; Davies, MJ
  • The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010
    Stark Casagrande, S; Fradkin, JE; Saydah, SH; Rust, KF; Cowie, CC
  • Addressing barriers to initiation of insulin in patients with type 2 diabetes
    Peyrot, M; Rubin, RR; Khunti, K
  • Does clinical inertia vary by personalized A1C goal? A study of predictors and prevalence of clinical inertia in a U.S. managed-care setting
    Lin, J; Zhou, S; Wei, W; Pan, C; Lingohr-Smith, M; Levin, P
  • Patient non-adherence and healthcare-provider inertia are clinical myopia
    Reach, G
  • Clinical inertia
    Phillips, L; Branch, W; Cook, C
  • Clinical inertia in the management of type 2 diabetes metabolic risk factors
    Grant, RW; Cagliero, E; Dubey, AK
  • Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy
    Nichols, GA; Koo, YH; Shah, SN
  • Low rate of intensification in type 2 diabetic patients inadequately controlled with basal insulin: the INTERDIA study
    Roussel, R; Gourdy, P; Gautier, JF
  • Effect of improved glycemic control on health care costs and utilization
    Wagner, EH; Sandhu, N; Newton, KM; McCulloch, DK; Ramsey, SD; Grothaus, LC
  • Health outcomes associated with initiation of basal insulin after 1, 2, or ≥ 3 oral antidiabetes drug(s) among managed care patients with type 2 diabetes
    Levin, PA; Zhou, S; Gill, J; Wei, W
  • The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus
    Smolen, HJ; Murphy, DR; Gahn, JC; Yu, X; Curtis, BH
  • Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study
    Bonafede, M; Chandran, A; DiMario, S; Saltiel-Berzin, R; Saliu, D
  • Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA
    Mauricio, D; Meneghini, L; Seufert, J
  • Treatment intensification for patients with type 2 diabetes and poor glycaemic control
    Fu, AZ; Sheehan, JJ
  • A real-world observational study of time to treatment intensification among elderly patients with inadequately controlled Type 2 Diabetes Mellitus
    Ajmera, M; Raval, A; Zhou, S
  • The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy
    Thayer, S; Wei, W; Buysman, E
  • Initiating injectable therapy in US managed care patients with diabetes
    Levin, P; Lin, J; Wei, W
  • Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting
    Davis, SN; Wei, W; Garg, S
  • Adding rapid-acting insulin or GLP-1 receptor agonist to basal insulin: outcomes in a community setting
    Dalal, MR; Xie, L; Baser, O; DiGenio, A
  • “Act on threes” paradigm for treatment intensification of type 2 diabetes in managed care: results of a randomized controlled study with an educational intervention targeting improved glycemic control
    Bieszk, N; Reynolds, SL; Wei, W; Davis, C; Kamble, P; Uribe, C
  • Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment
    Ayyagari, R; Wei, W; Cheng, D; Pan, C; Signorovitch, J; Wu, EQ
  • Administrative and claims records as sources of health care cost data
    Riley, GF
  • Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes
    Carls, GS; Tuttle, E; Tan, RD; Huynh, J; Yee, J; Edelman, SV; Polonsky, WH
  • Persistence with Insulin therapy in patients with type 2 diabetes in France: an insurance claims study
    Roussel, R; Charbonnel, B; Behar, M; Gourmelen, J; Emery, C; Detournay, B